C05AA11 fluocinonide
CARDIOVASCULAR SYSTEM ›VASOPROTECTIVES ›AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE ›Corticosteroids
非健保收載 TFDA 在效許可證 1 FDA 已核准
台灣藥品與外觀
無外觀照
氟欣諾能
資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 抗發炎劑。
美國 FDA 適應症(英文原文對照)
1 INDICATIONS AND USAGE Fluocinonide cream USP, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older. ( 1 ) Limitation of Use: Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. ( 1 ) Avoid use on the face, groin, or axillae. ( 1.2 ) Avoid use in perioral dermatitis or rosacea. 1.1 Indication Fluocinonide cream USP, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older [ see Use in Specific Populations (8.4) ]. 1.2 Limitation of Use Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because the safety of fluocinonide cream USP, 0.1% for longer than 2 weeks has not been established and because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Therapy should be discontinued when control of the disease is achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary. Do not use more than half of the 120 g tube per week. Fluocinonide cream USP, 0.1% should not be used in the treatment of rosacea or perioral dermatitis, and should not be used on the face, groin, or axillae.
資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。
健保給付規定
查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。